|
Index | - | P/E | - | EPS (ttm) | -2.33 | Insider Own | 15.73% | Shs Outstand | 40.47M | Perf Week | 15.85% |
Market Cap | 192.00M | Forward P/E | - | EPS next Y | -1.10 | Insider Trans | 0.00% | Shs Float | 34.13M | Perf Month | 34.56% |
Income | -82.70M | PEG | - | EPS next Q | -0.26 | Inst Own | 77.90% | Short Float | 5.93% | Perf Quarter | 18.45% |
Sales | - | P/S | - | EPS this Y | 0.00% | Inst Trans | 5.23% | Short Ratio | 8.57 | Perf Half Y | -29.73% |
Book/sh | 5.34 | P/B | 0.89 | EPS next Y | -13.40% | ROA | -43.60% | Target Price | 17.00 | Perf Year | -76.58% |
Cash/sh | 4.68 | P/C | 1.02 | EPS next 5Y | 32.10% | ROE | -58.20% | 52W Range | 3.02 - 20.59 | Perf YTD | -29.73% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -76.93% | Beta | - |
Dividend % | - | Quick Ratio | 48.80 | Sales past 5Y | - | Gross Margin | - | 52W Low | 57.28% | ATR | 0.37 |
Employees | 14 | Current Ratio | 48.80 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 68.71 | Volatility | 11.96% 9.53% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 67.70% | Profit Margin | - | Rel Volume | 0.00 | Prev Close | 4.75 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | May 16 AMC | Payout | - | Avg Volume | 235.98K | Price | 4.75 |
Recom | 1.60 | SMA20 | 21.16% | SMA50 | 27.00% | SMA200 | -33.91% | Volume | 0 | Change | 0.00% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. | ||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite